Efficacy and Safety of Adalimumab Biosimilar GP2017 in a 24-Month Treatment Period for Plaque Psoriasis: Real-Life Experience from Emilia-Romagna Centers, Italy. Dermatol Reports 2025. https://doi.org/10.4081/dr.2025.10315.